Literature DB >> 9108322

Conformational properties of the prion octa-repeat and hydrophobic sequences.

C J Smith1, A F Drake, B A Banfield, G B Bloomberg, M S Palmer, A R Clarke, J Collinge.   

Abstract

We have used circular dichroism to study synthetic peptides from two important regions of the prion protein: the N-terminal octa-repeat domain and a highly conserved hydrophobic section. Our results show that the octa-repeat sequence in free solution can adopt a non-random, extended conformation with properties similar to the poly-L-proline type II left-handed helix. We also show that the conformation can be changed by temperature, organic solvents (e.g. acetonitrile) and on binding to phospholipid vesicles. We compared CD data from two peptides corresponding to the hydrophobic region between residues 106 and 136 which contained either methionine or valine at position 129. This variation represents a common polymorphism in humans which has been shown to influence predisposition towards iatrogenic and sporadic CJD. There was no detectable difference between the CD spectra of these peptides irrespective of the solvent conditions we used.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9108322     DOI: 10.1016/s0014-5793(97)00220-2

Source DB:  PubMed          Journal:  FEBS Lett        ISSN: 0014-5793            Impact factor:   4.124


  13 in total

1.  Molecular modelling indicates that the pathological conformations of prion proteins might be beta-helical.

Authors:  D T Downing; N D Lazo
Journal:  Biochem J       Date:  1999-10-15       Impact factor: 3.857

2.  Structure of the recombinant full-length hamster prion protein PrP(29-231): the N terminus is highly flexible.

Authors:  D G Donne; J H Viles; D Groth; I Mehlhorn; T L James; F E Cohen; S B Prusiner; P E Wright; H J Dyson
Journal:  Proc Natl Acad Sci U S A       Date:  1997-12-09       Impact factor: 11.205

3.  Post-translational hydroxylation at the N-terminus of the prion protein reveals presence of PPII structure in vivo.

Authors:  A C Gill; M A Ritchie; L G Hunt; S E Steane; K G Davies; S P Bocking; A G Rhie; A D Bennett; J Hope
Journal:  EMBO J       Date:  2000-10-16       Impact factor: 11.598

4.  Prion nucleation site unmasked by transient interaction with phospholipid cofactor.

Authors:  Ashley A Zurawel; Daniel J Walsh; Sean M Fortier; Tamutenda Chidawanyika; Suvrajit Sengupta; Kurt Zilm; Surachai Supattapone
Journal:  Biochemistry       Date:  2014-01-02       Impact factor: 3.162

5.  Copper binding to octarepeat peptides of the prion protein monitored by mass spectrometry.

Authors:  R M Whittal; H L Ball; F E Cohen; A L Burlingame; S B Prusiner; M A Baldwin
Journal:  Protein Sci       Date:  2000-02       Impact factor: 6.725

6.  Molecular dynamics simulations of two tandem octarepeats from the mammalian prion protein: fully Cu2+-bound and metal-free forms.

Authors:  M Jake Pushie; Hans J Vogel
Journal:  Biophys J       Date:  2007-08-17       Impact factor: 4.033

7.  Structure of the flexible amino-terminal domain of prion protein bound to a sulfated glycan.

Authors:  Lara M Taubner; Ewa A Bienkiewicz; Valérie Copié; Byron Caughey
Journal:  J Mol Biol       Date:  2009-11-10       Impact factor: 5.469

8.  Conformation of prion protein repeat peptides probed by FRET measurements and molecular dynamics simulations.

Authors:  Marsia Gustiananda; John R Liggins; Peter L Cummins; Jill E Gready
Journal:  Biophys J       Date:  2004-04       Impact factor: 4.033

9.  Structure-Dependent Interfacial Properties of Chaplin F from Streptomyces coelicolor.

Authors:  Mina Dokouhaki; Emma L Prime; Andrew Hung; Greg G Qiao; Li Day; Sally L Gras
Journal:  Biomolecules       Date:  2017-09-19

Review 10.  Prion Protein at the Leading Edge: Its Role in Cell Motility.

Authors:  Mariana Brandão Prado; Maria Isabel Melo Escobar; Rodrigo Nunes Alves; Bárbara Paranhos Coelho; Camila Felix de Lima Fernandes; Jacqueline Marcia Boccacino; Rebeca Piatniczka Iglesia; Marilene Hohmuth Lopes
Journal:  Int J Mol Sci       Date:  2020-09-12       Impact factor: 5.923

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.